Athersys has regularly filed patent applications (including composition of matter and/or method of usage, as appropriate) related to proprietary product candidates arising from its lead development efforts and its cell therapy development activities. Currently, the Company has over 20 patent applications directed to product candidates and their therapeutic uses.
Athersys' RAGE technology portfolio includes 11 issued U.S. patents, and multiple pending U.S. patent applications, and various corresponding international patents and patent applications. Further, Athersys has also filed patent applications covering novel human gene sequences and new drug targets discovered using RAGE, and multiple applications directed to novel mutation methods (GECKO technology).
Athersys' MultiStem intellectual property consists of ownership of and an exclusive worldwide license from the University of Minnesota to the MAPC technology and its uses, together with intellectual property developed at Athersys. Currently, the portfolio consists of one issued U.S. patent and more than 20 pending U.S. patent applications and various corresponding international patent applications.